Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal (GI) disorder that affects 20% of Americans. The motility changes in IBS are driven by changes in the enteric nervous system (ENS). IBS has no cure, but recently, a neurokinin‐2 receptor (NK2R) antagonist has been shown to improve overall symptoms in a phase II study of diarrhea‐predominant IBS. However, the effects of NK2R antagonists on the ENS are not understood. We hypothesize that the beneficial effects of this antagonist on IBS are, in part, due to effects on the ENS. We tested our hypothesis by treating mice with the NK2R antagonist GR 159897 in a dinitrobenzene sulfonic acid (DNBS) model of colitis. To assess changes in the ENS, we used immunohistochemistry to quantify neuronal survival and performed a glial morphology analysis to assess reactive gliosis in the ENS. Calcium imaging recordings were performed in tissue preparations from mice expressing the genetically‐encoded calcium indicator GCaMP5g expressed under the control of the SOX10 promoter (SOX10::creERT2/+; PC::G5‐TdT+/−) or by loading cells with the calcium indicator dye Fluo4‐AM. Our results show that treatment with GR 159897 prevents increases in glial fibrillary acid protein (GFAP) immunoreactivity (n= 3–4 mice; p= 0.0141), increases in glial process length (n= 9–12 glia; p= 0.013) and neurodegeneration (n = 3–4; p= 0.0028). Immunohistochemical and calcium imaging data show that enteric glia express NK2Rs that are activated by neurokinin‐A (NKA). Glial responses to NKA were decreased in the presence of GR 159897 (n= 101–113 glia; p= 0.0001) or tetrodotoxin and were significantly reduced in samples from mice lacking glial connexin‐43 hemichannels (SOX10::creERT2/+; Cx43f/f mice; n= 50–113 glia; p= 0.0001). Glial responses to NKA were completely abolished in tissue samples from SOX10::creERT2/+; Cx43f/f mice in the presence of GR 159897 (n= 34–113; p= 0.0001). In conclusion, our data demonstrate that GR 159897 provides neuroprotection during colitis through mechanisms that involve decreasing glial activity driven by NKA. We speculate that these mechanisms could explain some of the clinical benefits of current NK2R antagonists in IBS.Support or Funding InformationRO1DK103723‐02S1